Leqvio is not a statin. It belongs to a completely different class of drugs called RNA interference (RNAi) therapeutics. While both Leqvio and statins lower LDL cholesterol, they work through entirely different biological mechanisms, are taken in different ways, and are typically used together rather than as substitutes for each other.
How Leqvio Works Differently From Statins
Statins lower cholesterol by blocking an enzyme in the liver that your body needs to produce cholesterol. They’re daily pills you take at home, and they’ve been the cornerstone of cholesterol management for decades.
Leqvio (the brand name for inclisiran) takes a fundamentally different approach. It’s a small interfering RNA, a tiny piece of genetic material that silences a specific gene in your liver cells. That gene produces a protein called PCSK9, which normally breaks down the receptors your liver uses to pull LDL cholesterol out of your bloodstream. By shutting down PCSK9 production, Leqvio allows more of those receptors to survive and keep clearing cholesterol from your blood. The end result is lower LDL, but the path to get there has nothing in common with how a statin operates.
Why Leqvio Is Used With Statins, Not Instead of Them
The FDA approved Leqvio specifically as an add-on therapy, not a replacement. It’s indicated for adults with an inherited form of high cholesterol (heterozygous familial hypercholesterolemia) or existing cardiovascular disease who are already on the highest statin dose they can tolerate and still need further LDL reduction. In clinical practice, most patients receiving Leqvio have already been optimized on a statin, sometimes combined with other cholesterol-lowering medications, and their LDL levels remain too high.
Because the two drugs lower cholesterol through independent pathways, their effects can stack. In the major clinical trials (ORION-10 and ORION-11), patients who were already on statin therapy saw an additional LDL reduction of roughly 50% when Leqvio was added. ORION-10 showed a 52.3% reduction and ORION-11 showed a 49.9% reduction over about 17 months.
How Leqvio Is Given
Unlike a statin, which you swallow daily at home, Leqvio is a subcutaneous injection given by a healthcare professional. You cannot self-administer it. The dosing schedule is straightforward: one injection to start, a second injection at three months, and then one injection every six months after that. For many people, the appeal is that after the initial doses, you’re only visiting a clinic twice a year for cholesterol management rather than remembering a daily pill.
If you miss a scheduled dose by less than three months, you can pick up where you left off. If more than three months have passed, you restart the sequence: an initial injection, another at three months, then every six months going forward.
Side Effects Compared to Statins
Statins are well known for causing muscle pain and soreness in some patients, along with occasional liver enzyme changes. These side effects are one of the main reasons some people can’t tolerate higher statin doses.
Leqvio doesn’t carry those same muscle-related risks. In clinical trials, its side effect profile was similar to placebo, with one notable exception: reactions at the injection site, such as redness, pain, or swelling where the shot was given. This is a meaningful distinction for people who experience statin intolerance, since Leqvio offers a way to achieve significant additional LDL lowering without compounding those muscle symptoms. For patients who are fully statin-intolerant, Leqvio can also be used without any statin at all.
Who Is a Candidate for Leqvio
Leqvio isn’t a first-line treatment for high cholesterol. It fills a specific gap for higher-risk patients. You’d typically be considered a candidate if you have atherosclerotic cardiovascular disease (meaning you’ve already had a heart attack, stroke, or have significant plaque buildup in your arteries) or if you have an inherited cholesterol condition, and your LDL remains elevated despite taking the maximum statin dose your body can handle. Some patients also take ezetimibe or other lipid-lowering drugs before Leqvio enters the conversation.
If your cholesterol responds well to a statin alone, Leqvio likely isn’t necessary. It’s designed for the subset of patients where statins, even at full strength, aren’t enough to bring LDL to a safe level.